Jonathan Cox
Cardiovascular Disease · Philadelphia, PANPI 1013987544
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 272 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,737 and has fallen 85.7% since, to $248 in 2022.
Across 272 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$741
- Johnson & Johnson$695
- Pfizer$568
- Amarin Pharma, Inc.$533
- Boston Scientific$418
- Sanofi-aventis U.S. LLC$404
- plus $1K from 15 others
What the payments were for
- Food & beverage$4,62596%
- Education$1794%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 36 | $741 |
| Johnson & Johnson(2 entities) | 36 | $695 |
| Pfizer | 37 | $568 |
| Amarin Pharma, Inc. | 33 | $533 |
| Boston Scientific | 16 | $418 |
| Sanofi-aventis U.S. LLC | 23 | $404 |
| Boehringer Ingelheim | 15 | $255 |
| Astellas Pharma US Inc | 10 | $159 |
| Regeneron Healthcare Solutions, Inc. | 8 | $146 |
| Kowa Pharmaceuticals America, Inc. | 10 | $134 |
| Esperion Therapeutics, Inc. | 8 | $125 |
| Gilead | 8 | $112 |
| AstraZeneca | 7 | $107 |
| E.r. Squibb & Sons, L.L.C. | 7 | $91 |
| Novartis | 6 | $77 |
| Althera Pharmaceuticals LLC | 3 | $66 |
| Merck | 3 | $57 |
| Impulse Dynamics (USA) Inc. | 2 | $46 |
| Abbott | 2 | $35 |
| Medtronic | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$106
How this compares
$4,804 in reported general payments places this provider in the 70th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Philadelphia
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Dean KaralisPhiladelphia$385K
- Manavendra BakhshiPhiladelphia$250K
- Philip HainesPhiladelphia$170K
- Julio ChirinosPhiladelphia$145K
- Michael MillerPhiladelphia$133K
- Nehal MehtaPhiladelphia$129K
- Garo GaribianPhiladelphia$115K
- Norman FeinsmithPhiladelphia$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.